Comfort Systems USA Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Comfort Systems USA Inc trades at $1,676.4 (market cap $61.14B), while Vertex Pharmaceuticals Incorporated trades at $482.32 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is the larger of the two by market cap, and Comfort Systems USA Inc pays a 0.15% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| FIX | VRTX | |
|---|---|---|
Market Cap | $61.14B | $121.09B |
Sector | Technology | Health |
52-Week High | $2.07K | $529.59 |
52-Week Low | $532.14 | $366.54 |
Enterprise Value | $60.42B | $115.83B |
Dividend Yield | 0.15% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vertex Pharmaceuticals (VRTX) trades at $476.31, down 0.82% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $4.47, and maintains robust profitability with a net income margin of 35.51%. Recent news highlights a $10 billion acquisition of Crinetics Pharmaceuticals, aimed at expanding its endocrinology portfolio with potential peak sales of over $5 billion.
The outlook remains positive with analyst consensus favoring a buy rating (83.92%) and a price target of $538, suggesting 13% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments, while strong cash flow and earnings growth support long-term value.
Trailing returns across standard periods
Latest headlines on both assets
Comfort Systems USA is a premier provider of mechanical and electrical contracting services. It specializes in HVAC, plumbing, and energy management solutions for commercial and industrial facilities.
Read more on FIX →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →